- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: Hodgkin's Disease - February 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de febrero del 2002
Table of Contents
1
UI - 11764473
AU - Pajunen M
TI -
[Late adverse effects of the Hodgkin's disease therapy]
SO - Duodecim 2000;116(2):148-52
AD - Keski-Suomen keskussairaala, Sadesairaala, syopatautien ja sadehoidon
yksikko Keskussairaalantie 19 40620 Jyvaskyla. marjo.pajunen@ksshp.fi
2
UI - 11778565
AU - Zhou L; Wang Q; Feng F
TI -
[Treatment of advanced Hodgkin's disease: an analysis of 128 cases]
SO - Zhonghua Zhong Liu Za Zhi 2000 Jul;22(4):333-5
AD - Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking
Union Medical College, Beijing 100021, China.
OBJECTIVE: To explore the rational treatment for advanced Hodgkin's
disease. METHODS: A total of 128 patients with advanced Hodgkin's
disease was included in this study. They could be divided into 3 groups
according to the treatment they received. Patients in group 1 (n = 99)
were treated by combination chemotherapy plus radiotherapy. Patients in
group 2 (n = 24) were treated by chemotherapy alone. The remaining 5
patients in group 3 were treated by radiotherapy alone. The
chemotherapeutic regimens used were MOPP, MOPP alternating with CHOP, or
with ABVD. RESULTS: The overall response rate of 127 evaluable patients
was 96.1%. The overall 1-, 3-, 5, and 10-year survival rate was 91.4%,
70.3%, 56.8% and 52.4%, respectively. The complete response (CR) rate in
the 3 groups of patients was 69.7%, 58.3% and 100%, respectively.
Patients in clinical stage III with no bulky mass, no systemic symptoms,
and their tumor was predominantly of lymphocytic or nodular sclerotic
type had better long term survival than those in clinical stage IV with
bulky mass, systemic symptoms, and with lymphocyte depleting, mixed
cellular tumor. Better long term survival was seen in patients who
showed complete response to combined chemotherapy and radiotherapy. At
least 6 cycles of chemotherapy were needed. CONCLUSION: Combination
chemotherapy plus radiotherapy is effective in the treatment of advanced
Hodgkin's disease.
3
UI - 11815953
AU - Clodi K; Asgari Z; Younes M; Palmer JL; Cabanillas F; Carbone A;
TI -
Andreeff M; Younes A
Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin
disease: potential therapeutic significance.
SO - Cancer 2002 Jan 1;94(1):1-5
AD - St. Anna Kinderspital, Vienna, Austria.
BACKGROUND: The malignant Hodgkin and Reed-Sternberg (H/RS) cells of
Hodgkin disease (HD) express CD30 and CD40 receptors that can activate
nuclear factor kappa B and transduce survival signals. The authors have
reported previously that the B lymphocytes of HD express CD30 ligand
(CD30L, CD153). Furthermore, they and others have reported previously
that the CD40L survival pathway is augmented in patients with B-cell
malignancies, as CD40L was constitutively expressed by the malignant B
cells and infiltrating T cells, and sera from those patients contained
elevated levels of soluble CD40L. In this study, the authors
investigated the hypothesis that the survival of H/RS cells was
similarly promoted by an augmented CD40L signals in HD patients.
METHODS: The expression of CD40L on lymphocyte subsets of patients with
classic HD was determined by two-color fluorescent-activated cell sorter
analysis. Serum soluble CD40L levels were determined by enzyme linked
immunosorbent assay. RESULTS: CD40L was constitutively expressed on both
the T and B cells of HD patients but was more prominently expressed on
the B lymphocytes. Soluble CD40L was detected in the serum of 17 of 37
patients (45%) and was higher than 1 ng/mL in 4 patients (10%). Both
interleukin (IL)-4 and IL-10, which are known to be secreted by H/RS
cells and surrounding T cells, up-regulated CD40L expression on normal B
cells. CONCLUSIONS: Thus, the expression of CD40L and CD30L on the B
cells of HD patients suggests that B lymphocytes may play a role in the
regulation of H/RS cell growth in vivo. Depriving H/RS cells from CD30L
and CD40L survival signals by eliminating B cells from HD lesions may be
of therapeutic value. Copyright 2002 American Cancer Society.
4
UI - 11138810
AU - Vineis P; Crosignani P; Vigano C; Fontana A; Masala G; Stagnaro E;
TI -
Miligi L; Costantini AS; Nanni O; Ramazzotti V; Rodella S; Tumino R;
Vindigni C
Lymphomas and multiple sclerosis in a multicenter case-control study.
SO - Epidemiology 2001 Jan;12(1):134-5
5
UI - 11554622
AU - Moody AM; Pratt J; Hudson GV; Smith P; Lamont A; Williams MV
TI -
British National Lymphoma Investigation: pilot studies of neoadjuvant
chemotherapy in clinical stage Ia and IIa Hodgkin's disease.
SO - Clin Oncol (R Coll Radiol) 2001;13(4):262-8
AD - Oncology Centre, Addenbrooke's NHS Trust, Cambridge, UK.
In order to improve treatment in early Stage IA and IIA Hodgkin's
disease, the British National Lymphoma Investigation (BNLI) has
evaluated two neoadjuvant chemotherapy regimens with involved field
radiotherapy. This article reports the results of the methotrexate,
vinblastine and prednisolone (MVP) study in 39 patients and updates the
previous report on vinblastine, bleomycin and methotrexate (VBM) in 30
patients. Both studies recruited clinical Stage IA or IIA Hodgkin's
disease patients with intermediate risk of relapse into a prospective
multicentre Phase II study. They received two cycles of chemotherapy
followed by involved field radiotherapy and then four further cycles of
chemotherapy. For MVP the 5-year survival is 97% and for VBM it is 93%.
The 5-year event-free survival rates are 71% and 87% respectively. The
acute pulmonary and haematological toxicity occurring with VBM was not
acceptable and therefore the MVP study was performed. There was less
toxicity with this regimen although modest acute pulmonary toxicity was
still observed. However, in view of the length of treatment with MVP (9
months) and the excellent results reported by the Manchester group,
future efforts of the BNLI are to be directed towards a new short course
chemotherapy regimen, VAPEC-B (vincristine, doxorubicin, prednisolone,
etoposide, cyclophosphamide and bleomycin).
6
UI - 11775214
AU - Deng F; Liao L; Lu G; Li G; Yang G
TI -
A study of Hodgkin/Reed-Sternberg cells using single cell polymerase
chain reaction.
SO - Chin Med J (Engl) 2000 Jan;113(1):65-9
AD - Department of Pathology, Zunyi Medical College, Zunyi 563003, China.
OBJECTIVE: To investigate the characteristics of Hodgkin/Reed-Stemberg
(H/R-S) cells found in patients with various types of Hodgkin's disease
(HD). METHODS: H/R-S cells were micropicked from frozen sections of
tissues affected by HD. The DNA from these cells was amplified by
polymerase chain reaction (PCR) using immunoglobulin heavy chain gene FR
III a/JH primers and light chain gene family-specific primers. RESULTS:
A total of 52/135 (35.8%) isolated cells showed the specific products in
the reactions. IgH and V kappa 4 rearrangements were repeatedly found in
many cells from a lymphocyte predominance type sample; repeated V kappa
4 and individual IgH/V kappa 2,4 rearrangements and individual IgH, V
lambda 3/ V kappa 4 rearrangements were found in two different cases of
the nodular sclerosis type; repeated IgH/ V lambda 3 and individual V
lambda 2,4 rearrangements, repeated V kappa 2,4 rearrangements, repeated
V kappa 4 and individual IgH/ V kappa 3 rearrangements, repeated IgH and
individual V kappa 3/ V lambda 4 rearrangements were detected in 3 cases
of the mixed cellularity type. Repeated and individual IgH
rearrangements were found in other 2 cases. CONCLUSION: The H/R-S cells
isolated from the lymphocyte predominance subtypes of HD have IgH and V
lambda 4 gene rearrangements. This suggests that the lymphocyte
predominance type is a proliferation of neoplastic B cells. The cells
isolated from the mixed cellularity and nodular sclerosis types derive
from B lineage cells at various stages of differentiation because of the
presence of their IgH, kappa and/or lambda gene rearrangements. To our
knowledge, this is the first time that the lambda gene rearrangement was
detected in H/R-S cells.
7
UI - 11714108
AU - Clarke CA; Glaser SL; Prehn AW
TI -
Age-specific survival after Hodgkin's disease in a population-based
cohort (United States).
SO - Cancer Causes Control 2001 Nov;12(9):803-12
AD - Surveillance Research, Northern California Cancer Center, Union City, CA
94587, USA. tclarke@nccc.org
OBJECTIVE: To examine risk factors for disease-specific survival in
young and older adults diagnosed with Hodgkin's disease (HD) in a
representative case series of adequate size for detecting effect
modification by age group. METHODS: For 5630 young adults (ages 15-44)
and 2424 older adults (ages 45 and older) diagnosed with HD and reported
to the population-based Surveillance, Epidemiology, and End Results
program of the National Cancer Institute between 1983 and 1995,
Kaplan-Meier survival curves were constructed and Cox proportional
hazards regression used to evaluate the influences of age, sex,
race/ethnicity, histologic subtype, Ann Arbor stage at diagnosis, and
calendar year on hazard of disease-specific death. RESULTS: The effects
of most previously studied risk factors for HD death were different for
young and older adults. Age was not associated with disease-specific
survival in young adults, but in older adults, 1-year increases in age
elevated the relative hazard of HD death by 4 6%. Male sex was related
to outcome in young but not older adults, and Ann Arbor stage and
B-symptom status exhibited markedly different relationships to survival
by age. Older adult patients with and without B-symptoms had different
hazards of mortality and had to be assessed separately. CONCLUSIONS:
Factors associated with disease-specific survival were different for
young and older adults with HD. These findings provide further support
for two etiologically and clinically distinct disease entities.
8
UI - 11781246
AU - Skinnider BF; Elia AJ; Gascoyne RD; Patterson B; Trumper L; Kapp U; Mak
TI -
TW
Signal transducer and activator of transcription 6 is frequently
activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
SO - Blood 2002 Jan 15;99(2):618-26
AD - Amgen Institute and Department of Oncologic Pathology, Ontario Cancer
Institute, Toronto, Canada.
The unique clinicopathologic features of Hodgkin lymphoma (HL) are due
to the multiple cytokines produced by its neoplastic cells, the Hodgkin
and Reed-Sternberg (HRS) cells. Cytokine signaling is mediated through
the signal transducer and activator of transcription (STAT) family of
transcription factors. Immunoblotting and immunohistochemistry were used
to examine cell lines and tissue sections derived from patients with HL
and non-Hodgkin lymphoma (NHL) for expression of activated STAT
proteins. Constitutive phosphorylation of STAT6 and STAT3 was common in
HL. STAT6 was constitutively phosphorylated in 5 of 5 HL cell lines and
in HRS cells from 25 of 32 (78%) classical HL cases. STAT3 was
constitutively phosphorylated in 4 of 5 HL cell lines and in HRS cells
from 27 of 31 (87%) classical HL cases. Only 4 of 24 NHL cases
demonstrated constitutive STAT6 activation, whereas STAT3 activation was
observed in 6 of 13 (46%) cases of B-cell NHL and 8 of 11 (73%) cases of
T-cell NHL. Constitutive STAT5 phosphorylation was not a common feature
of HL or NHL. STAT6 mediates signaling by interleukin 13 (IL-13), a
cytokine frequently expressed by HRS cells. Antibody-mediated
neutralization of IL-13 resulted in significant decreases in both
cellular proliferation and levels of phosphorylated STAT6 of HL cell
lines. In conclusion, constitutive STAT6 phosphorylation is a common and
distinctive feature of HRS cells in classical HL, whereas STAT3
activation was regularly present in both HL and NHL. These results
suggest that IL-13 signaling is largely responsible for the constitutive
STAT6 activation observed in HRS cells and further implicate IL-13 as an
important growth factor in classical HL.
9
UI - 11781255
AU - Harty LC; Lin AY; Goldstein AM; Jaffe ES; Carrington M; Tucker MA; Modi
TI -
WS
HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease.
SO - Blood 2002 Jan 15;99(2):690-3
AD - Genetic Epidemiology Branch and the Laboratory of Pathology, National
Cancer Institute, Bethesda, MD 20892-7236, USA.
The HLA region has long been implicated in sporadic and familial Hodgkin
disease (HD), with recent case-control studies suggesting that HLA class
II loci predispose to sporadic nodular sclerosis HD (NSHD). To determine
whether this predisposition extends to familial HD, HLA class II loci
(DRB1, DQA1, DQB1, DRB3, DRB4, and DRB5) and transporter associated with
antigen processing (TAP) loci (TAP1, TAP2) were investigated in 100
members of 16 families with at least 2 confirmed cases of HD. With the
use of the transmission disequilibrium test, evidence for linkage
disequilibrium with familial HD and, in particular, familial NSHD was
obtained for the DRB1*1501-DQA1*0102-DQB1*0602 haplotype, the TAP1
allele encoding Ile at residue 333, and the DRB5-0101 allele. These 3
markers were in linkage disequilibrium and may not represent independent
susceptibility regions. Use of a family-based approach excludes
population stratification as an explanation for these findings.
10
UI - 11781257
AU - Kang EM; de Witte M; Malech H; Morgan RA; Phang S; Carter C; Leitman SF;
TI -
Childs R; Barrett AJ; Little R; Tisdale JF
Nonmyeloablative conditioning followed by transplantation of genetically
modified HLA-matched peripheral blood progenitor cells for hematologic
malignancies in patients with acquired immunodeficiency syndrome.
SO - Blood 2002 Jan 15;99(2):698-701
AD - Molecular and Clinical Hematology Branch, National Institute of Diabetes
and Digestive and Kidney Diseases, National Institutes of Health,
Bethesda, MD 20892, USA.
To assess the safety and efficacy of nonmyeloablative allogeneic
transplantation in patients with HIV infection, a clinical protocol was
initiated in patients with refractory hematologic malignancies and
concomitant HIV infection. The results from the first 2 patients are
reported. The indications for transplantation were treatment-related
acute myelogenous leukemia and primary refractory Hodgkin disease in
patients 1 and 2, respectively. Only patient 1 received genetically
modified cells. Both patients tolerated the procedure well with minimal
toxicity, and complete remissions were achieved in both patients, but
patient 2 died of relapsed Hodgkin disease 12 months after
transplantation. Patient 1 continues in complete remission with
undetectable HIV levels and rising CD4 counts, and with both the
therapeutic and control gene transfer vectors remaining detectable at
low levels more than 2 years after transplantation. These results
suggest that nonmyeloablative allogeneic transplantation in the context
of highly active antiretroviral therapy is feasible in patients with
treatment-sensitive HIV infection.
11
UI - 11781710
AU - Vockerodt M; Tesch H; Kube D
TI -
Epstein-Barr virus latent membrane protein-1 activates CD25 expression
in lymphoma cells involving the NFkappaB pathway.
SO - Genes Immun 2001 Dec;2(8):433-41
AD - Klinik fur Innere Medizin I, Zentrum fur Molekulare Medizin der
Universitat zu Koln, D-50924 Koln, Germany.
Martina.Vockerodt@medizin.uni-koel.de
Epstein-Barr virus (EBV) is associated with several human malignancies
including Burkitt's lymphoma (BL), Hodgkin's disease (HD) and
nasopharyngeal carcinoma. A variety of cytokines and receptors have been
described to be activated by EBV. Here we show that the IL-2 receptor
(IL-2R) alpha-chain, which is weakly expressed on normal resting
lymphoid cells, is activated by EBV. Comparison of EBV-negative BL cell
lines and their EBV convertants showed an enhanced CD25 expression in
EBV-positive BL cells. Transient expression of the oncogenic virus
protein latent membrane protein-1 (LMP1) in L428 Hodgkin's lymphoma
cells and in Burkitt's lymphoma cells (BL2, BL41, BL30) cells leads to
enhanced CD25 expression. Both C-terminal activating regions (CTARs) of
LMP1 are involved in CD25 activation. Inhibition of LMP1-mediated
NFkappaB enhancement by a constitutive repressive form of IkappaB-alpha
resulted in decreased CD25 surface expression, indicating that NFkappaB
is involved in CD25 gene regulation. Furthermore, LMP1-mediated CD25
activation was associated with enhanced levels of the soluble form of
CD25 (sCD25) in L428 Hodgkin's lymphoma cells but not in BL cells. LMP1
associated enhanced expression of membrane CD25 and soluble CD25 may
have immunomodulatory functions and could be involved in biology of
EBV-associated diseases.
12
UI - 11697623
AU - Axdorph U; Porwit-MacDonald A; Grimfors G; Bjorkholm M
TI -
Tissue eosinophilia in relation to immunopathological and clinical
characteristics in Hodgkin's disease.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):1055-65
AD - Department of Medicine, Karolinska Hospital and Institutet, Stockholm,
Sweden. ulla.axdorph@ks.se
Eosinophils frequently infiltrate tissues involved by Hodgkin's disease
(HD), and blood eosinophilia is frequently observed. However, the
clinical significance and the mechanisms underlying eosinophilia need
further elucidation. In this study the grade of eosinophilic
infiltration (EoI) was evaluated in biopsies from 259 HD-patients. In a
selected group (n=32), the numbers of Hodgkin-Reed-Sternberg (HRS)-cells
were counted, and the phenotype of small lymphocytes, the expression of
cytotoxic lymphocyte-associated proteins, CD3-zeta-chain, HLA-DR,
proliferation markers, latent membrane protein 1 (LMP-1) and blood
lymphocyte function were evaluated. Samples from 88 HD patients (34%)
showed high EoI. Significantly higher EoI was seen in nodular sclerosis
2 (NS2; p<0.001), bulky disease (p<0.05) and in patients <50 years
(p<0.05). Patients with high EoI did not differ from the remainder with
regard to distribution of sex, stage, B-symptoms, blood lymphocyte
function and outcome. HRS-cells were significantly more frequent in NS
HD as compared to mixed cellularity (MC) (p<0.001) irrespective of EoI.
LMP-1-expression, proliferative fraction and phenotypes of small
lymphocytes did not differ between the cases with low and high EoI,
respectively. MC HD samples had significantly higher numbers of small
cells positive for CD8 (p<0.01), T-cell intracellular antigen-1 (p<0.01)
and Granzyme B (p<0.05) than NS. LMP-1-positive cases had significantly
higher frequency of CD8-positive cells than LMP-1-negative. In
conclusion, high EoI remains a feature of certain clinical subgroups of
HD. However, there was no association between the degree of EoI and
numbers of HRS-cells, phenotypes of small lymphocytes, EBV status and
clinical outcome. Determination of EoI is of limited diagnostic and
prognostic clinical value in HD. However, the differences in small cell
distribution of CD8, TIA-1, GrB and CD57 between the histopathological
groups and between LMP-1-expressing/non-expressing cases may contribute
to our understanding of the biology of the disease.
13
UI - 11697652
AU - Herling M; Rassidakis GZ; Viviani S; Bonfante V; Giardini R; Gianni M;
TI -
Morris SW; Cabanillas F; Medeiros LJ; Sarris AH
Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease:
results with ALK-11 antibody in 327 untreated patients.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):969-79
AD - Department of Lymphoma-Myeloma, The University of Texas M.D. Anderson
Cancer Center, Houston 77030, USA.
The t(2;5)(p23;q35) or other rare chromosomal abnormalities involving
2p23 upregulate the ALK gene, which is not expressed in normal
lymphocytes. Thus, detection of ALK protein is presumptive evidence of
these 2p23 abnormalities. The t(2;5) and ALK immunoreactivity are common
in anaplastic large cell lymphoma of T/null-cell lineage. However, a
small subset of cases of Hodgkin's disease (HD) have been reported to
either carry the t(2;5) or express ALK. In this study, we have
immunohistochemically evaluated 327 cases of HD with the ALK-11
antibody. ALK-11 is a well characterized polyclonal antibody raised
against an intracellular portion of the ALK protein. We detected ALK-11
immunoreactivity in 8 (2.4%) cases of HD. We further studied these
positive cases with ALK-1 monoclonal antibody, which reacts with an
intracellular portion of ALK, similar to ALK-11. All 8 ALK-11 positive
cases were negative for ALK-1. These results indicate that rare cases of
HD may react with ALK-11 antibody, similar to previous reports by others
using different polyclonal anti-ALK antibodies. However, the absence of
ALK-1 expression in these HD cases suggests that ALK protein is not
truly present and that polyclonal anti-ALK antibodies may rarely yield
non-specific cross reactivity. These results further support the use of
anti-ALK antibodies in the differential diagnosis of HD from ALCL.
14
UI - 11697655
AU - Glase SL; Clarke CA; Stearns CB; Dorfman RF
TI -
Age variation in Hodgkin's disease risk factors in older women: evidence
from a population-based case-control study.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):997-1004
AD - Northern California Cancer Center, Union City 94587, USA.
Hodgkin's disease (HD), which affects all age groups, has been
associated with childhood social class, particularly among adults under
age 40. Little is known about social class risk factors in older adults,
and the few existing studies have conflicting findings. As part of a
population-based case-control study of HD in women, we examined social
class risk factors by diagnostic age groups (45-54 years and 55-79
years) corresponding to incidence patterns and by histologic subtypes
based on a uniform pathologic review. Among women ages 45-54, cases were
more likely to be Catholic, to have lower income and to be taller than
controls. Among women ages 55-79, cases tended to have come from small
or large childhood households, lived in single-family childhood housing,
and had a single rather than shared bedroom at age 11. For the nodular
sclerosis (NS) histologic subtype, similar age differences in risk
factors were apparent. Comparisons between the NS and non-NS subtypes in
women ages 55-79 identified some common risk factors (single-family
childhood home, single bedroom at age 11) but others specific to one
subtype (childhood household size, adult height for NS; lower maternal
education for non-NS). Thus, some social class associations with HD
differed between middle-aged and older women, as well as between these
groups and younger adults, while others were shared across age groups.
Risk also was associated with both higher and lower childhood social
class in middle-aged and older women, in contrast with previous
findings. None of these patterns was explained entirely by histologic
subtype but may reflect age and histology subtype variation in the
HD-EBV association.
15
UI - 11780584
AU - Wojtukiewicz MZ; Sawicki Z; Dzieciol J
TI -
A rare localization of Hodgkin's disease in the breast--a case report.
SO - Rocz Akad Med Bialymst 2001;46():87-90
AD - Department of Oncology, Medical Academy of Bialystok, Bialystok, Poland.
In this paper we present a rare localization of Hodgkin's disease--in
the breast. An awareness of such unusual clinical presentation of
Hodgkin's disease is important to prevent a delay in diagnosis and
treatment.
16
UI - 11426545
AU - Santon A; Bellas C
TI -
Deletions within the epstein-barr virus latent membrane protein-1
oncogene in adult ordinary, HIV-associated and paediatric Hodgkin's
disease.
SO - Leuk Lymphoma 2001 Jan;40(3-4):235-42
AD - Pathology Department, Hospital Ramon y Cajal, Madrid, Spain.
The aims of this study were the following: a) to perform Epstein-Barr
virus (EBV) strain type assignment in three groups of Hodgkin's
disease(HD): adult ordinary (39 cases), paediatric (24 cases), and
HIV-associated (30 cases) and to compare the prevalence of type 1 and
type 2 in each of the groups with that existing in two reference
populations made up of 50 adults and 39 children; b) to assess the
frequency of latent membrane protein-1 (LMP-1) 30-base pair (bp)
deletions in the HD groups and in the healthy controls; and c) to relate
the presence of LMP-1 deletions with EBV type. Type 2 EBV was observed
in 12.8% of ordinary HD, in 26.7% of HIV-associated HD, in 25% of
paediatric HD, in 4% of adult controls, and in none of the healthy
children. The existence of double infections by type 1 and 2 EBV was
also observed in 5.1% of ordinary HD, in 6.7% of HIV-associated HD, and
in 10% of adult controls. The 30-bp deletion was identified overall in
33.3% of ordinary HD, in 83.3% of HIV-positive HD, 79.2% of paediatric
HD, 34.7% of adult controls, and 36.4% of healthy children. Statistical
analysis showed a significant association of the deleted strains with HD
occurring in HIV-positive patients (P= 0.00003) and childhood HD (P=
0.006). On the other hand, the prevalence of the 30-bp deletion in the
adult ordinary HD group reflects the prevalence of the deletion in the
general population. Co-infections by deleted and non-deleted EBV strains
were detected in 12.8% of ordinary HD, in 33.3% of HIV-associated HD, in
50% of paediatric HD, in 26.5% of adult controls, and in 27.3% of
healthy children. Concerning the relationship between the deletion and
the EBV typing, 26% of type 1 specimens carried the 30-bp deletion in an
isolated manner compared with 64.7% of type 2. The statistical analysis
showed that the deletion was associated with type 2 strains when
coinfections were excluded and only the cases in which the deletion
appeared alone were considered (P=0.003).
17
UI - 11426558
AU - Wiernik PH; Leong T; Oken MM; Neiman RS; Habermann TM; Bennett JM;
TI -
Schuster S; Glick JH
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and
prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed
after radiotherapy alone: a long-term follow-up study of the Eastern
Cooperative Oncology Group (E3481).
SO - Leuk Lymphoma 2001 Jan;40(3-4):357-63
AD - OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466,
USA. wiernik@jimmy.harvard.edu
Thirty-three evaluable patients with Hodgkin's disease who failed
radiotherapy were treated on this phase II study with bleomycin,
lomustine, cyclophosphamide, vincristine, procarbazine and prednisone
given every 28 days for a minimum of eight courses. Twenty-five patients
(76%; 95% CI=55.6-87.1%) achieved a complete remission, the median
duration of which cannot yet be determined, but the probability of
remaining in continuous complete remission at 10 years is.64. The median
survival from entry on this study for all evaluable patients is 10
years, and 12 patients were alive at the time of this analysis with a
median follow-up for them of 15.5 years. Of the 22 patients who died, 11
died of progressive or recurrent Hodgkin's disease and 11 died of other
causes including 7 second primary neoplasms and at least one myocardial
infarction. Both are now well known late complications of Hodgkin's
disease treatment.
18
UI - 11426570
AU - Miyazaki M; Miyakoshi S; Kami M; Mori M; Kishi Y; Inagawa H; Machida U;
TI -
Matsumura T; Kawagoe S; Ueyama J; Morinaga S; Matsushita H; Muto Y
Systemic fusariosis after a preparative regimen including thiotepa,
VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's
disease.
SO - Leuk Lymphoma 2001 Jan;40(3-4):441-4
AD - Dept of Hematology, Toranomon Hospital, Tokyo, Japan.
Fusarium infection is rare but important infection after bone marrow
transplantation (BMT). A 27-year-old man developed systemic fusarial
infection following severe skin damage probably caused by high-dose
thiotepa administration. Systemic fusariosis rapidly progressed to a
variety of organs despite antifungal treatment, and he finally died of
this infection on day 75. Considering that this organism usually invades
via damaged skin and that the penile lesion was the first manifestation
of systemic fusariosis in this patient, careful examination of the skin
might be helpful for early diagnosis of fusarial infection. His clinical
course provided us with an important clue for diagnosis of fusarial
infection.
19
UI - 11583202
AU - Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R
TI -
Transformation of Hodgkin's disease to high-grade B-cell lymphoma:
remission after Rituximab monotherapy.
SO - Ann Oncol 2001 Aug;12(8):1169-71
AD - Abteilung fur Hamatologie/Onkologie, Katholisches Marienhospital Herne,
Universitatsklinik, Germany.
PURPOSE: We demonstrate the usefulness of immunotherapy with the CD20
antibody Rituximab in a case of transformation of Hodgkin's disease (HD)
to high-grade non-Hodgkin's lymphoma (NHL). CASE REPORT: A 45-year-old
women suffering from lymphocyte predominant HD of paragranuloma type
(stage IVb) since 1995 showed mediastinal relapse despite of 6 cycles of
chemotherapy following the COPP/ABVD-protocol in 1998. Again complete
remission could be achieved after escalated BEA-COPP II therapy in May
1998. Six months later chest radiograph and CT depicted pulmonary
nodules. The non-typical resection of the lung revealed pulmonary
involvement of a high-grade T-cell rich large B-cell lymphoma with 100%
of the tumoral cells CD20 positive. Since the symptoms occurred shortly
after the BEA-COPP-escalated protocol chemotherapy resistance had to be
assumed. Because of this problems and supported by the refusal of a
high-dose chemotherapy with stem-cell transplantation by the patient we
decided to perform a mono-immunotherapy with the monoclonal CD20
antibody Rituximab. Today, 14 months later, the patient is still in
complete remission including the absence of B symptoms. CONCLUSIONS:
Immunotherapy against CD20 positive cells in cases of sequential HD and
NHL seems to be an effective therapy in chemotherapy resistant cases
because of the suspected clonally relation of both diseases.
20
UI - 11786751
AU - Gundlapalli S; Ojha B; Mountz JM
TI -
Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in
outpatient positron emission tomographic facilities for patients
receiving ongoing treatment of lymphoma.
SO - Clin Nucl Med 2002 Feb;27(2):140-1
AD - Division of Nuclear Medicine, Department of Radiology, University of
Alabama at Birmingham Medical Center, Birmingham, Alabama, USA.
21
UI - 11530527
AU - Lazarev IM
TI -
[Cytological characteristics of Hodgkin disease with nodular sclerosis]
SO - Klin Lab Diagn 2001 Jul;(7):24, 33-5
Cellular characteristics of tumor with nodular sclerosis verified
histologically were retrospectively studied on puncture biopsy specimens
of involved lymph nodes from 57 patients with cytologically verified
Hodgkin's disease (lymphogranulomatosis). "Lacunar" cells in different
combinations with three types (mononuclear, "mirror", and multinuclear)
of Berezovskii-Sternberg cells and "reticular" cells were detected in
80.7% cases. The lymphoid component was presented by lymphocytes and
prolymphocytes. Cell composition of the tumor in Hodgkin's disease with
nodular sclerosis should be regarded as combination of tumor growth with
reactive hyperplasia of the lymphoid tissue at the level of lymphocytes
and prolymphocytes.
22
UI - 11697828
AU - Anonymous
TI -
ESMO minimum clinical recommendations for diagnosis, treatment and
follow-up of Hodgkin's disease.
SO - Ann Oncol 2001 Sep;12(9):1213-4
23
UI - 11697845
AU - Rueffer U; Breuer K; Josting A; Lathan B; Sieber M; Manzke O;
TI -
Grotenhermen FJ; Tesch H; Bredenfeld H; Koch P; Nisters-Backes H; Wolf
J; Engert A; Diehl V
Male gonadal dysfunction in patients with Hodgkin's disease prior to
treatment.
SO - Ann Oncol 2001 Sep;12(9):1307-11
AD - First Department of Internal Medicine, University Hospital Cologne, and
the German Hodgkin's Study Group.
Infertility after treatment of patients with Hodgkin's disease (HD) is
considered as a side effect of alkylating agent containing chemotherapy
regimens. To investigate whether gonadal failure is related primarily to
the toxic effect of chemotherapy or rather to the disease itself, we
investigated the fertility status before the onset of treatment.
PATIENTS AND METHODS: Semen quality and hormonal status were evaluated
in 158 patients with first diagnosis of HD enrolled into trials of the
German Hodgkin Lymphoma Study Group (GHSG). The median age of the
patients was 28 years (range 16-52). Twenty patients (13%) were
classified as early stage HD, 63 patients (40%) as intermediate stage,
and 75 patients (47%)) as advanced stage according GHSG grading.
Sixty-seven patients (42%) showed systemic symptoms. Semen analysis was
performed according to WHO guidelines. Follicle-stimulating hormone
(FSH) and luteinising hormone (LH) plasma levels were measured by
specific double-antibody radio-immune-assay (RIA) methods. RESULTS:
Prior to treatment, severe damage of fertility, i.e.. azoospermia and
oligoasthenoteratospermia (OAT-syndrome) was found in 13 (8%) and 20
patients (13%), respectively. Thirty-eight patients (24%) had single,
i.e., oligo-(O), astheno-(A) or teratospermia-(T), and 40 patients (26%)
showed combined damages, i.e., OA, OT or AT. In 47 patients (30%) a
normal sperm count was found. Thus, III patients (70%) showed semen
abnormalities before the onset of treatment. In a multivariate analysis
elevated ESR (P < 0.003) and advanced stage of disease (P < 0.01) could
be distinguished as prognostic factors for severe damage of fertility.
No correlation was found between pre-therapeutic gonadotropine levels
and fertility status. CONCLUSION: Patients with HD have an increased
risk for inadequate semen quality even prior to treatment. Infertility
is more frequent in patients with elevated ESR and advanced stage of
disease. This association demonstrates the predominant influence of the
disease on fertility. Assuming HD is the major initial cause for
infertility efforts should be made to identify new non-gonadal toxic
chemotherapies to be able to regain fertility after effective therapy.
Further investigations have to be performed to clarify mechanisms
inducing fertility defects in patients with HD.
24
UI - 11748461
AU - Meng Q; Lai H; Lima J; Tong W; Qian Y; Lai S
TI -
Echocardiographic and pathological characteristics of cardiac metastasis
in patients with lymphoma.
SO - Oncol Rep 2002 Jan-Feb;9(1):85-8
AD - Department of Emergency Medicine, Chinese PLA General Hospital, Beijing,
P.R. China.
The purposes of this study were to investigate the patterns of lymphoma
involvement in the heart and to correlate pathologic findings in the
heart at autopsy with echocardiographic presentation prior to death in
patients with malignant lymphoma. Lymphoma patients with complete
echocardiographic records prior to death and conformed cardiac
metastasis at autopsy were included in the study. Echocardiographic
records were reviewed retrospectively. Pathological diagnoses were
compared with echocardiographic findings using Fisher's exact test.
Twenty-nine patients aged 19-71 (mean +/- SD, 51.5+/-12.7) years were
included in the study. Among them 17 (58.6%) were male. There were 6
cases (20.7%) with Hodgkin's disease and 23 (79.3%) cases with
non-Hodgkin's lymphoma. Twenty-two (75.9%) cases were diagnosed with
cardiac metastases at autopsy by gross appearance of their hearts. The
most common (41.4%) site of metastatic involvement was the pericardium.
The frequency of tumor on the valves was significantly lower than in the
chambers and on other parts of the heart (6.9% versus 93.1%). Metastatic
masses in right heart were found in 8 (8/23, 34.8%) non-Hodgkin's
lymphoma cases, which was higher than that in Hodgkin's lymphoma cases
(0/6, 0%; p=0.15). The frequency of high-grade non-Hodgkin's disease
metastasizing to the right ventricle was significantly higher than that
for the other kinds of lymphoma (3/7, 42.9% versus 0/22, 0%; p=0.01).
Sensitivity of echocardiographic examination to detect cardiac
metastasis was 75.9%. Echocardiography has been shown to be a sensitive
method for the diagnosis of cardiac involvement in the patients with
lymphoma. Patterns of cardiac involvement vary by the types of lymphoma,
suggesting that different pathologic types of lymphoma may have
different mechanisms of metastasis to the heart.
25
UI - 11863222
AU - Gulley ML; Glaser SL; Craig FE; Borowitz M; Mann RB; Shema SJ; Ambinder
TI -
RF
Guidelines for interpreting EBER in situ hybridization and LMP1
immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin
lymphoma.
SO - Am J Clin Pathol 2002 Feb;117(2):259-67
AD - Department of Pathology, University of Texas Health Science Center at
San Antonio, USA.
Histochemical stains demonstrate Epstein-Barr virus (EBV) in
approximately 40% of all Hodgkin hymphomas, suggesting a role in
tumorigenesis and the potentialfor EBV-targeted therapy. As research
progresses, it is important to define criteria for interpreting
histochemical stains. Four hematopathologists independently interpreted
EBV-encoded RNA (EBER) and latent membrane protein 1 (LMP1)
histochemical stains from 40 cases of Hodgkin lymphoma and then reviewed
the stains as a group to resolve discrepancies and to develop
interpretation guidelines. To call a Hodgkin case EBV-related, the EBER
and/or LMP1 signal must be unequivocally present in
Reed-Sternberg/Hodgkin (RS/H) cells. The cytologic features and
distribution of stained cells should be matched with those on the
corresponding H&E-stained slide to help interpret whether the EBER or
LMP1 signal is in malignant or reactive cells. The EBER signal is
localized to the nucleus, whereas LMP1 is in the cytoplasm and surface
membrane. In some cases, only a fraction of RS/H cells express these
factors for technical or biologic reasons. Before calling a case
EBER-negative, it is essential to show that tumor cell RNA is preserved
and available for hybridization. LMP1 staining, although usually strong
among all tumor cells in a given case, may alternatively be focal and
weak, contributing to false-negative interpretation. EBER and LMP1
assays in combination are more effective than either assay alone for
identifying EBV-related Hodgkin lymphoma.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
